Accelerated approval is likely to be used more extensively in the future for gene therapies that treat very rare diseases, but the slowly progressive nature of some conditions means there may be many years of uncertainty about the clinical benefits provided by the one-time treatments, the head of the US FDA’s Office of Tissues and Advanced Therapies said.
OTAT Director Wilson Bryan opined on the future use of accelerated approval for gene therapies, worries about ambiguous confirmatory trial...